论文部分内容阅读
目的探讨恩替卡韦治疗失代偿期乙型肝炎肝硬化的临床疗效。方法选择2011年5月~2013年4月本院门诊及住院的失代偿期乙型肝炎肝硬化患者80例,将其随机分为观察组和对照组各40例,对照组采用常规性保肝治疗,观察组在对照组的基础上采用国产恩替卡韦治疗。治疗48周后比较两组治疗前后的HBV-DNA、肝功能、肝纤维化指标。结果治疗前两组HBV-DNA、肝功能指标ALT、AST、TBiL、ALB,肝纤维化指标HA、LN、PⅢP、CⅣ比较,差异均无统计学意义(P>0.05);治疗后观察组HBV DNA,ALT、AST、TBiL、ALB,HA、LN、PⅢP、CⅣ均优于对照组,差异有统计学意义(P<0.05)。结论恩替卡韦能治疗失代偿期乙型肝炎肝硬化,可有效抑制病毒复制,改善肝功能及肝纤维化程度,值得临床推广应用。
Objective To investigate the clinical efficacy of entecavir in the treatment of decompensated hepatitis B cirrhosis. Methods 80 patients with decompensated hepatitis B cirrhosis from May 2011 to April 2013 in our hospital were selected and randomly divided into observation group and control group with 40 cases in each group. Liver treatment, the observation group in the control group based on the use of domestic entecavir treatment. After 48 weeks of treatment, HBV-DNA, liver function and liver fibrosis indexes before and after treatment were compared. Results There was no significant difference in HBV-DNA, ALT, AST, TBiL, ALB, HA, LN, PⅢP and CⅣ between the two groups before treatment (P> 0.05) DNA, ALT, AST, TBiL, ALB, HA, LN, PⅢP, CⅣ were all better than the control group, the difference was statistically significant (P <0.05). Conclusion Entecavir can treat cirrhosis of patients with decompensated hepatitis B, which can effectively inhibit virus replication and improve liver function and liver fibrosis. It is worthy of clinical application.